Tristel Plc · LSE:TSTL
Tristel — ShareSoc Leeds (April 2026)
26 slides from Tristel's conference presentation, April 2026
Slide 1: Tristel plc at ShareSoc Leeds Investor Presentation
TRISTEL PLC AT SHARESOC LEEDS INVESTOR PRESENTATION Anna Wasyl, CFO APRIL 2026 tristelgroup.com 1
Slide 2: Our Company
Our Company We are a global infection prevention company. The entire purpose of our business is to prevent the transmission of microbes from one object or person to another. We achieve our mission by applying a very powerful biocidal chemistry – chlorine dioxide – to the target environmental surface
Slide 3: Key Indicators
Key Indicators 50,000 40,000 COVID 10-year CAGR at Revenue £'000 30,000 11.7% and 14% Strong Record in H1 Revenue Growth 20,000 revenue growth in H2 H1 2026 10,000 - 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 14,000 12,000 Short term investments Continuous strong 10,000 cash generat
Slide 4: Balance Sheet KPIs
Balance Sheet KPIs 60,000 17% 50,000 Net working Downward trend in NWC capital as a percentage of revenue Healthy 40,000 16% highlights enhanced liquidity Net Working 30,000 Revenues past 12 months and efficient operations, Capital 20,000 15% 10,000 positioning the company well NWC/Revenue - 14% 12
Slide 5: Our Product Portfolios
Our Product Portfolios 8% High level disinfection Hospital surface & of medical devices equipment disinfection Ambition: Ambition: Global market Global market leader in leader in point of care sporicidal decontamination disinfection for of medical critical healthcare devices settings £1b £398m S erv
Slide 6: The Impact of Our Products
The Impact of Our Products Medical Device Disinfection Medical Surface Disinfection How we win: How we win: Convenience Compatibility Efficacy Faster Disinfection at point Approved to be used Broader spectrum & Speed of action vs of procedure with ‘000s of devices sporicidal abilities typical method
Slide 7: Global Market Trends
Global Market Trends 1 5 Continuous expansion of devices Growing awareness on the being used during percutaneous negative impact of biofilms procedures, requiring HLD 2 6 Constant threat of antimicrobial Increased utilisation of ultrasound resistance and the resultant high at the point of care costs
Slide 8: Executing on the Opportunity
Executing on the Opportunity Geographical Refined Surface Expanding Product Digital Expansion Disinfection Clinical Reach Portfolio Leadership Strategy and Influence Expansion tristelgroup.com 8
Slide 9: H1 2026 Revenues by Geography
H1 2026 Revenues by Geography • 19 subsidiaries with 279 employees globally UK • 42 distributors serving £9.9m further 40 countries 12.9% • Continuous growth in Europe with ongoing investments to accelerate penetration APAC £4.0m • Americas gaining traction EMEA 0.3% with more than sixfold Americas
Slide 10: USA – Ultrasound Opportunity
USA – Ultrasound Opportunity Market Size Market Split Market Strategy (Ultrasound Scans requiring HLD) Approximately 270,000 ultrasound devices in North America. 2. Soaking (25%) Across 5,700 1. Trophon relevant hospitals (50%) 3. Wiping Manufacturing & with departments and/or Distribution partner u
Slide 11: US Tristel ULT Sales
US Tristel ULT Sales Tristel ULT estimated sales and royalties in the US market ($’000) • Royalty income $153k 1,200 • 320,000 procedures (x3 growth YoY) 1,000 981 • Over 400 active users with 90 added in the last 3 months 800 • Increasing utilisation among existing users 600 548 • Healthy pipeline
Slide 12: USA – Customer Success Examples
USA – Customer Success Examples “I can confidently “Tristel ULT is faster “Purchasing Tristel ULT "Tristel has been a recommend Tristel ULT. and easier to use than has been a lifesaver! game changer for our both Cidex and Trophon, sonographers, providing The product is just as We run a super busy wi
Slide 13: USA – Ophthalmology Opportunity
USA – Ophthalmology Opportunity Market Size Market Split Market Strategy (Current methodologies) Ophthalmic devices that Mixed Sales Model touch the eye must undergo High-Level Disinfection (HLD) after every use. 1. Soaking 2. Low level Wipes Products manufactured by Parker but sold by Tristel. Circ
Slide 14: US Tristel OPH Sales
US Tristel OPH Sales Tristel OPH sales in the US market Sep-Dec 2025 ($'000) • Product launched in September 2025 • H1 FY26 revenues at $88k exceeding initial expectations Estimated In Market Sales • 40,000 customer procedures performed • 43 accounts using, 84 evaluating and 76 engaged • Strong part
Slide 15: Our 2025–2030 Financial Commitments
Our 2025–2030 Financial Commitments Metric Target Timeframe Revenue Growth Double Digit Annually FY25–FY30 EBITDA* Margin ≥25% Annually Every Year Dividend Policy Progressive YoY Growth Ongoing * Excluding Share Based Payments tristelgroup.com 15
Slide 16: Growth Scenarios
Growth Scenarios 100 CAGR 17% 90 Opportunities for more 80 CAGR 10% aggressive growth 70 coming from: 60 50 11.7% CAGR • US market expansion £m 40 • New product launches 30 • Software 20 commercialisation 10 - • Inorganic opportunities 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Slide 17: Why invest?
Why invest? 1 2 3 4 Niche, Strong Market Proven Track Resilient, Defensive Scalable Global Position with High Record of Growth, Business Model Strategy Barriers to Entry Profitability and Regulatory approvals Shareholder Returns Company operates in in 30+ countries. infection prevention, an Technolo
Slide 18: Questions
QUESTIONS tristelgroup.com 18
Slide 19: Appendix
APPENDIX tristelgroup.com 19
Slide 20: Market Opportunity by Specialty
Market Opportunity by Specialty Ultrasound ENT Ophthalmology Surfaces Invasive and non-invasive Single and non-lumened Reusable devices such as Surfaces and equipment in ultrasound devices. flexible endoscopes. tonometer prisms and high-risk healthcare settings. diagnostic lenses. 200 million proced
Slide 21: The Power of Chlorine Dioxide
The Power of Chlorine Dioxide Multiple An oxidising Broad Unlike chlorine, Per molecule is Due to molecular Tristel chlorine effective substance with spectrum does not 263% more size and gaseous dioxide is rapid modes of an unstable efficacy readily form reactive than nature in solution acting with
Slide 22: Tristel vs Competition
Tristel vs Competition Early findings from existing markets are now confirmed in the US Customer experience with Customer experience following disinfection machines Tristel product introduction • Inefficient workflow due to transportation • Significant cost reduction of the probes, machine warm up c
Slide 23: Tristel ULT Guidelines and Testimonials
Tristel ULT Guidelines and Testimonials ANSI/AAMI ST58:2024 – Chemical sterilization and high-level disinfection in health care facilities “Our recent TJC audit went great, they [Joint Commission] love Tristel ULT and were very excited that we were using it. Link: ANSI/AAMI ST58:2024 - Chemical ster
Slide 24: Digital Leadership
Digital Leadership Compliance Tools Advancing Digital Platforms • 3T currently offers interactive product training and full • 3T is evolving to a multi-tier SaaS model, where a free tier remains - offering all global customers access to training digital traceability for medical device reprocessing a
Slide 25: ESG Strategy - Doing the Right Thing, the Right Way
ESG Strategy - Doing the Right Thing, the Right Way Pillar 1: Creating safe, effective products is core to our business. 1 We’re committed to developing sustainable solutions and reducing waste through thoughtful design. • Innovation • Waste management and a circular economy Pushing the boundaries o
Slide 26: Sustainability – FY25 Key Success Areas
Sustainability – FY25 Key Success Areas Net Zero & Social Value: Sustainable Solutions • MSCI ESG Ratings – AAA • Aligned with UN SDGs • SBTi 1.5°C Targets Approved • UK Living Wage Employer • Carbon Reduction Plan Development • 44% Females in STEM Roles • Product Carbon Footprint (PCF) • Modern Sla